GlassScriptPhysician profile
Bernard M Weiner
NPI 1356390660
$3,601.97
in general payments reported to CMS, 2019-2025
33 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $421 · 2021: $310 · 2022: $225 · 2023: $607 · 2024: $511 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657 · Education: $65.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.33 |
| Education | $65.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $490.98 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $440.60 | 2019-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.50 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $322.19 | 2019-2020 | |
| Akebia Therapeutics INC | $268.21 | 2019-2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $195.24 | 2019-2022 | |
| Lilly USA, LLC | $171.81 | 2019-2024 | Jardiance, Mounjaro |
| Travere Therapeutics, INC. | $164.11 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $143.75 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.67 | 2021-2025 | |
| Vifor Pharma, INC. | $112.73 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $93.78 | 2022-2023 | Velphoro |
| Calliditas Therapeutics US INC. | $85.80 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $78.23 | 2021-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $59.09 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $51.23 | 2025 | |
| Ardelyx, INC. | $49.13 | 2024 | Ibsrela |
| Shield Therapeutics INC | $45.51 | 2023 | Accrufer |
| Ani Pharmaceuticals, INC. | $44.37 | 2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $38.85 | 2020-2023 | Benlysta |
| Amarin Pharma, INC. | $36.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.85 | 2022 | |
| Kyowa Kirin, INC. | $27.47 | 2023 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.21 | 2023 | Jynarque |
| Renalytix Ai, INC. | $24.00 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Opko Pharmaceuticals, LLC | $21.03 | 2023 | Rayaldee |
| Horizon Therapeutics Plc | $20.06 | 2019 | |
| Exact Sciences Corporation | $19.42 | 2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $18.49 | 2023 | Givlaari |
| Pfizer INC. | $15.05 | 2019 | |
| Sanofi Pasteur INC. | $14.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.78 | 2019 | |
| Dexcom, INC. | $13.41 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.